nach oben

vorheriger Artikel Aggression und serotoninerge Dysfunktion

nächster Artikel Welche Behandlungen sind für unsere Patienten z...

Tipp

Therapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI)

Zeitschrift:: psychopraxis. neuropraxis > Ausgabe 1/2017

Autoren:: Dr. Wolfgang Novak, Andreas Erfurth

Zusammenfassung

Antidepressiva sind eine inhomogene Gruppe von Substanzen, unter denen sich die selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI) als First-line-Medikamente bei Depressionen etabliert haben. Der Vorteil der SSRI gegenüber Antidepressiva der ersten Generation liegt in ihrem günstigeren Nebenwirkungsprofil, der hohen therapeutischen Breite und den niedrigeren Drop-out-Raten bei vergleichbarer Wirksamkeit. Escitalopram und Sertralin zeichnen sich möglicherweise durch Wirksamkeitsvorteile gegenüber den anderen SSRI aus.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Möller H‑J, Laux G, Kapfhammer H‑P (Hrsg) (2011) Psychiatrie, Psychosomatik, Psychotherapie, 4. Aufl. Springer, Berlin Heidelberg

Jacobi F, Wittchen H‑U, Hölting C, Höfler M, Pfister H, Müller N, Lieb R (2004) Prevalence, co-morbiditiy and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey [GHS]. Psychol Med 34:1–15 CrossRef

Murray C, Lopez A (1997) Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504 CrossRefPubMed

Kasper S, Lehofer M, Doering S, Geretsegger C, Frey R, Haring C et al (2012) Depression – Medikamentöse Therapie. Clin Neuropsy (Sonderausgabe Nov 2012):3–23

Lohoff FW (2010) Overview of the genetics of major depressive disorder. Curr Psychiatry Rep 12(6):539–546 CrossRefPubMedPubMedCentral

aan het Rot M, Mathew SJ, Charney DS (2009) Neurobiological mechanisms in major depressive disorder. CMAJ 180(3):305–313 CrossRef

Linden M, Müller WE (2005) Rehabilitations-Psychopharmakotherapie: Arzneimittelbehandlung chronifizierender und chronifizierter psychischer Syndrome, 1. Aufl. Deutscher Ärzte-Verlag, Köln

Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1119–1127 CrossRef

Rothenhäusler H‑B, Täschner K‑L (2007) Kompendium Praktische Psychiatrie. Springer, Wien NewYork

10.

Müller H‑J, Laux G, Deister A (2009) Psychiatrie und Psychotherapie, 4. Aufl. Duale Reihe. Thieme, Stuttgart

11.

Benkert O, Hippius H (2013) Kompendium der Psychiatrischen Pharmakotherapie, 9. Aufl. Springer, Berlin Heidelberg CrossRef

12.

Lüllmann H, Mohr K, Hein L (2006) Pharmakologie und Toxikologie: Arzneimittelwirkungen verstehen – Medikamente gezielt einsetzen, 16. Aufl. Thieme, Stuttgart

13.

Beubler E (2011) Kompendium der Pharmakologie. Gebräuchliche Arzneimittel in der Praxis, 3. Aufl. Springer, Wien CrossRef

14.

Riederer P, Laux G, Pöldinger W (Hrsg) (2002) Neuro-Psychopharmaka, 2. Aufl. Bd. 3. Springer, Wien

15.

DeVane CL (1999) Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 19(4):443–466 CrossRefPubMed

16.

Kriegebaum C, Gutknecht L, Schmidt A, Lesch K‑P, Reif A (2010) Serotonin Kompakt – Teil 1: Neurobiologische und entwicklungsgenetische Grundlagen. Fortschr Neurol Psychiat 78:319–331 CrossRefPubMed

17.

Erfurth A, Gardier AM, Ribeiro E, Wurtman RJRJ (1994) Effects of subchronic pretreatment with D‑fenfluramine or p‑chloroamphetamine on [3 H]inositolmonophosphate accumulation in rat cortical miniprisms. Brain Res 665(1):107–114 CrossRefPubMed

18.

Gardier AM, Kaakkola S, Erfurth A, Wurtman RJ (1992) Effects of methiothepin on changes in brain serotonin release induced by repeated administration of high doses of anorectic serotoninergic drugs. Brain Res 588(1):67–74 CrossRefPubMed

19.

Kroeze Y, Zhou H, Homberg JR (2012) The genetics of selective serotonin reuptake inhibitors. Pharmacol Ther 136:375–400 CrossRefPubMed

20.

Mascio MD, Giovanni GD, Matteo VD, Prisco S, Esposito E (1998) Selective serotonin reuptake inhibitors reduce the spontaneus activity of dopaminergic neurons in the ventral tegmental area. Brain Res Bull 46(6):547–554 CrossRefPubMed

21.

Dremencov E, Mansari ME, Blier P (2009) Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J Psychiatry Neurosci 34(3):223–229 PubMedPubMedCentral

22.

Dremencov E, Mansari ME, Blier P (2007) Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry 61:671–678 CrossRefPubMed

23.

Castanon N, Leonard BE, Neveu PJ, Yirmiya R (2002) Effects of antidepressants on cytokine production and action. Brain Behav Immun 16:569–574 CrossRefPubMed

24.

Tao R, Calley CS, Hart J, Mayes TL, Nakonezny PA, Lu H et al (2012) Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry 169(4):381–388 CrossRefPubMedPubMedCentral

25.

Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr. (1992) The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 572(1–2):117–125 CrossRefPubMed

26.

Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010) Antidepressant drug effects and depression severity – a patient-level Meta-analysis. JAMA 303(1):47–53 CrossRefPubMedPubMedCentral

27.

Melander H, Salmonsen T, Abadie E, v. Zwieten-Boot B (2008) A regulatory apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 18:623–627 CrossRefPubMed

28.

Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS (2005) Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143(6):415–426 CrossRefPubMed

29.

Kennedy SH, Anderson HF, Lam RW (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Rev Psychiatr Neurosci 31(2):122–131

30.

Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgnis J, Churchill R et al (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758 CrossRefPubMed

31.

Barbui C, Hotopf M (2001) Amitriptyline versus the rest: still the leading antidepressant after 40 years of randomized controlled trials. Br J Psychiatry 178:129–144 CrossRefPubMed

32.

Anderson IM (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 58:19–36 CrossRefPubMed

33.

Spielmans GI, Berman MI, Usitalo AN (2011) Psychotherapy versus second-generation antidepressants in the treatment of depression. J Nerv Ment Dis 199(3):142–149 CrossRefPubMed

34.

Dreimüller N, Tadic A, Dragicevic A, Boland K, Bondy B, Lieb K et al (2012) The serotonin transporter promoter polymorphism [5-HTTLPR] affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry 45:108–113 CrossRefPubMed

35.

Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M (2009) SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiartr Genet Dec 19(6):281–291 CrossRef

36.

Young EA (2009) Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res 43(5):503–511 CrossRefPubMed

37.

Lee K‑U, Lee YM, Nam J‑M, Lee H‑K, Kweon Y‑S, Lee CT, Jun T‑Y (2010) Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investig 7:55–59 CrossRefPubMedPubMedCentral

38.

Trindade E, Menon D, Topfer L‑A, Coloma C (1998) Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 159(10):1145–1252

39.

Damsa C, Bumb A, Bianchi-Demicheli F, Vidailhet P, Sterck R, Andreoli A, Beyenburg S (2004) „Dopamine-dependent“ side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry August 65(8):1064–1068 CrossRef

40.

Hodge JM, Wang Y, Berg M, Collier FM, Fernandes TJ, Constable MJ et al (2012) Selective serotonin reuptake inhibitors inhibit human osteoclast and osteoblast formation and function. Biol Psychiatry 74:32. doi: 10.1016/j.biopsych.2012.11.003 CrossRefPubMed

41.

Barbui C, Esposito E, Cipriani A (2009) Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ 180(3):291–297 CrossRefPubMedPubMedCentral

42.

Leon AC, Salomon DA, Li C, Diedorowicz JG, Coryell WH, Endicott J, Keller MB (2011) Antidepressants and risk of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry 72(5):580–586 CrossRefPubMedPubMedCentral

43.

Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH (2003) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding – a population-based cohort study. Arch Intern Med 163:59–64 CrossRefPubMed

44.

Hackam DG, Mrkobrada M (2012) Selective serotonin reuptake inhibitors and brain hemorrhage. Neurology 79:1862–1865 CrossRefPubMed

45.

Barbey JT, Roose SP (1998) SSRI safety in overdose. J Clin Psychiatry 59(15):42–48 PubMed

46.

Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS et al (2012) Antidepressant response in patients with major depressive disorder exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 169:1065–1072 CrossRefPubMedPubMedCentral

47.

Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M et al (2007) World Federation of Societies of Biological Psychiatry [WFSBP] guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8(2):67–104 CrossRefPubMed

48.

Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003) Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64(4):413–420 CrossRefPubMed

49.

Posternak M, Baer L, Nierenberg AA, Fava M (2011) Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry 72(7):949–954 CrossRefPubMed

50.

Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006) Bupropion-SR, Sertralin, or Venlafaxin-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242 CrossRefPubMed

51.

Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661 CrossRefPubMed

52.

Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR Jr., Vazquez DM (2005) Selective Serotonin Reuptake Inhibitor [SSRI] use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 25:595–604 CrossRefPubMed

53.

Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ (2012) Who benefits from antidepressants? Synthesis of 6‑week patient-level outcomes from double-blind placebo controlled randomized trials of Fluoxetine and Venlafaxine. Arch Gen Psychiatry 69(6):572–557 PubMedPubMedCentral

54.

Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH (2016) Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 173(2):174–183 CrossRefPubMed

55.

Eke AC, Saccone G, Berghella V (2016) Selective serotonin reuptake inhibitor [SSRI] use during pregnancy and risk of preterm birth: a systematic review and meta-analysis. BJOG 123(12):1900–1907 CrossRefPubMed

56.

Alwan S, Friedman JM, Chambers C (2016) Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. CNS Drugs 30:499–515 CrossRefPubMed

57.

Viuff AC, Pedersen LH, Kyng K, Staunstrup NH, Børglum A, Henriksen TB (2016) Antidepressant medication during pregnancy and epigenetic changes in umbilical cord blood: a systematic review. Clin Epigenetics 8(1):94 CrossRefPubMedPubMedCentral

58.

Kremer M, Salvat E, Muller A, Yalcin I, Barrot M (2016) Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience 338:183–206 CrossRefPubMed

59.

Nazimek K, Strobel S, Bryniarski P, Kozlowski M, Filipczak-Bryniarska I, Bryniarski K (2016) The role of macrophages in anti-inflammatory activity of antidepressant drugs. Immunobiology:. doi: 10.1016/j.imbio.2016.07.001. PubMed

60.

Sachs G, Erfurth A (2015) Kognition bei depressiven Störungen. Psychoprax Neuroprax 18:172–179 CrossRef

61.

Rosenblat JD, Kakar R, McIntyre RS (2015) The cognitive effects of antidepressants in major depressive disorder: a systematic review and Meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol 19(2):pyv082. doi: 10.1093/ijnp/pyv082 CrossRefPubMedPubMedCentral

Titel: Therapie depressiver Störungen mit selektiven Serotonin-Rückaufnahme-Inhibitoren (SSRI)
Autoren:: Dr. Wolfgang Novak
Andreas Erfurth
Publikationsdatum: 01.02.2017
DOI: https://doi.org/10.1007/s00739-016-0371-5
Verlag: Springer Vienna
Zeitschrift: psychopraxis. neuropraxis Zeitschrift für praktische Psychiatrie und Neurologie
Ausgabe 1/2017
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Welche Behandlungen sind für unsere Patienten zielführend?

aktuell

Wie sieht die Versorgungsrealität in Österreich für Patienten mit komplexem Behandlungs- und Betreuungsbedarf aus?

Inzidentelle Befunde vaskulärer Ätiologie in der kranialen MRT

Diagnostik und Therapie des Morbus Parkinson

Aggression und serotoninerge Dysfunktion